TY - JOUR
T1 - Targeting the tumour microenvironment in ovarian cancer
AU - Hansen, Jean M.
AU - Coleman, Robert L.
AU - Sood, Anil K.
N1 - Funding Information:
JMH is supported by a NIH T32 Training Grant CA101642 . This work was also supported in part by NIH grants ( P50CA083639 , CA109298 , P50CA098258 , U54CA151668 , UH2TR000943 , CA177909 , CA016672 , U54CA96300 and U54CA96297 ), CPRIT RP 110595 , an Ovarian Cancer Research Fund Program Project Development Grant, Department of Defense Grants ( OC120547 and OC093416 ), The Betty Ann Asche Murray Distinguished Professorship , the RGK Foundation , the Gilder Foundation and the Blanton-Davis Ovarian Cancer Research Program .
Funding Information:
JMH and AKS report no conflicts of interest. RLC has clinical trial research grants from the National Cancer Institute, Abbvie, Clovis Oncology, AstraZeneca, Medimmune, Novartis, Oncomed, EMD-Serono, Array, Millennium, and Roche/Genentech. JMH is supported by a NIH T32 Training Grant CA101642. This work was also supported in part by NIH grants (P50CA083639, CA109298, P50CA098258, U54CA151668, UH2TR000943, CA177909, CA016672, U54CA96300 and U54CA96297), CPRIT RP 110595, an Ovarian Cancer Research Fund Program Project Development Grant, Department of Defense Grants (OC120547 and OC093416), The Betty Ann Asche Murray Distinguished Professorship, the RGK Foundation, the Gilder Foundation and the Blanton-Davis Ovarian Cancer Research Program.
Funding Information:
JMH and AKS report no conflicts of interest. RLC has clinical trial research grants from the National Cancer Institute, Abbvie, Clovis Oncology, AstraZeneca, Medimmune, Novartis, Oncomed, EMD-Serono, Array, Millennium, and Roche/Genentech.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - The study of cancer initiation, growth, and metastasis has traditionally been focused on cancer cells, and the view that they proliferate due to uncontrolled growth signalling owing to genetic derangements. However, uncontrolled growth in tumours cannot be explained solely by aberrations in cancer cells themselves. To fully understand the biological behaviour of tumours, it is essential to understand the microenvironment in which cancer cells exist, and how they manipulate the surrounding stroma to promote the malignant phenotype. Ovarian cancer is the leading cause of death from gynaecologic cancer worldwide. The majority of patients will have objective responses to standard tumour debulking surgery and platinum-taxane doublet chemotherapy, but most will experience disease recurrence and chemotherapy resistance. As such, a great deal of effort has been put forth to develop therapies that target the tumour microenvironment in ovarian cancer. Herein, we review the key components of the tumour microenvironment as they pertain to this disease, outline targeting opportunities and supporting evidence thus far, and discuss resistance to therapy.
AB - The study of cancer initiation, growth, and metastasis has traditionally been focused on cancer cells, and the view that they proliferate due to uncontrolled growth signalling owing to genetic derangements. However, uncontrolled growth in tumours cannot be explained solely by aberrations in cancer cells themselves. To fully understand the biological behaviour of tumours, it is essential to understand the microenvironment in which cancer cells exist, and how they manipulate the surrounding stroma to promote the malignant phenotype. Ovarian cancer is the leading cause of death from gynaecologic cancer worldwide. The majority of patients will have objective responses to standard tumour debulking surgery and platinum-taxane doublet chemotherapy, but most will experience disease recurrence and chemotherapy resistance. As such, a great deal of effort has been put forth to develop therapies that target the tumour microenvironment in ovarian cancer. Herein, we review the key components of the tumour microenvironment as they pertain to this disease, outline targeting opportunities and supporting evidence thus far, and discuss resistance to therapy.
KW - Ovarian cancer
KW - Tumour microenvironment
UR - http://www.scopus.com/inward/record.url?scp=84957564275&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957564275&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2015.12.016
DO - 10.1016/j.ejca.2015.12.016
M3 - Review article
C2 - 26849037
AN - SCOPUS:84957564275
SN - 0959-8049
VL - 56
SP - 131
EP - 143
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -